Pharmaceuticals News

Company Reports Record $31.0M Net Income and $53.7M Adjusted EBITDA(8) Announcing New HAUS Agreement with Entropy, an Upcoming HIP-3 Deployer 1 Million HYPE Tokens Redeployed to Support HIP-3 &...

Mechelen, Belgium; 12 August 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ:...

Mechelen, België; 12 augustus 2026, 22.01 CET; gereglementeerde informatie In het kader van het op 9 juni 2026 aangekondigde inkoopprogramma maakt Lakefront Biotherapeutics NV (Euronext & NASDAQ:...

Entered an exclusive license agreement with Innovent Biologics for SP001, a Phase 2-ready, third-generation anti-CD40L antibody for immune-mediated diseases U.S. Food and Drug Administration approved...

Total revenues were $18.5 million for the second quarter of 2026, reflecting 23% growth from the prior-year quarter  Emrosi® revenues were $8.1 million for the second quarter of 2026 Strong...

ISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a biopharmaceutical company focused on the development and commercialization of...

SANGAMO THERAPEUTICS SELECTS SUCCESSFUL BIDDERS FOLLOWING COMPETITIVE ASSET AUCTION

Applied Biologics announces National Health System Partnership Initiative to expand collaboration with health systems.

NeOnc’s (NASDAQ: NTHI) Phase 2a study of intranasal NEO100 in recurrent IDH1-mutant high-grade glioma met its primary endpoint

WILMETTE, Ill., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments...